Publications

Detailed Information

Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1

Cited 164 time in Web of Science Cited 171 time in Scopus
Authors

Na, Hye-Kyung; Surh, Young-Joon

Issue Date
2014-02
Publisher
Elsevier BV
Citation
Free Radical Biology and Medicine, Vol.67, pp.353-365
Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is an essential component of cellular defense against a vast variety of endogenous and exogenous insults, including oxidative stress. Nrf2 acts as a master switch in the circuits upregulating the expression of various stress-response proteins, especially heme oxygenase-1 (HO-1). Paradoxically, however, recent studies have demonstrated oncogenic functions of Nrf2 and its major target protein HO-1. Levels of Nrf2 and HO-1 are elevated in many different types of human malignancies, which may facilitate the remodeling of the tumor microenvironment making it advantageous for the autonomic growth of cancer cells, metastasis, angiogenesis, and tolerance to chemotherapeutic agents and radiation and photodynamic therapy. In this context, the cellular stress response or cytoprotective signaling mediated via the Nrf2-HO-1 axis is hijacked by cancer cells for their growth advantage and survival of anticancer treatment. Therefore, Nrf2 and HO-1 may represent potential therapeutic targets in the management of cancer. This review highlights the roles of Nrf2 and HO-1 in proliferation of cancer cells, their tolerance/resistance to anticancer treatments, and metastasis or angiogenesis in tumor progression. (C) 2013 Elsevier Inc. All rights reserved.
ISSN
0891-5849
URI
https://hdl.handle.net/10371/172723
DOI
https://doi.org/10.1016/j.freeradbiomed.2013.10.819
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Pharmacy
  • Department of Pharmacy
Research Area Agricultural Sciences

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share